Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolization for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patient factor~1. Age \> 18~2. Child-Pugh A or B cirrhosis~3. ECOG performance status Grade 2 or below~4. No serious concurrent medical illness~5. No prior treatment for HCC except for liver resection~6. Creatinine clearance \>55ml/min.~Tumor factor~1. HCC diagnosed by typical enhancement patterns on cross sectional imaging or histology.~2. Unresectable and locally advanced disease without extra-hepatic disease~3. Massive expansive tumor type with measurable lesion on CT~4. Total tumor mass \< 50% liver volume~5. Largest tumor of greatest dimension ≤ 15cm~Exclusion Criteria:~Patient factor~1. Serum creatinine level \> 130 umol/L~2. Presence of biliary obstruction not amenable to percutaneous drainage~3. Child-Pugh C cirrhosis~Evidence of impaired liver function~1. History of hepatic encephalopathy, or~2. Intractable ascites not controllable by medical therapy, or~3. History of variceal bleeding within last 3 months, or~4. Serum total bilirubin level \> 40 umol/L, or~5. Serum albumin level \< 30g/L, or~6. INR \> 1.3~Tumor factor~1. Presence of extrahepatic metastasis~2. Infiltrative lesion~3. Diffuse lesion~Vascular complications~1. Hepatic artery thrombosis, or~2. Partial or complete thrombosis of the main portal vein, or~3. Tumor invasion of portal branch of contralateral lobe, or~4. Hepatic vein tumor thrombus, or~5. Significant arterioportal shunt, or~6. Significant arteriovenous shunt

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TACE using a high dose of cisplatin (Type: OTHER): Two consecutive treatments at two months apart will be given. A delay in the second treatment is allowed if patients do not recover to an acceptable state for subsequent cycle of treatment. Two treatment sessions at one month apart may be required for each complete treatment to cover all lesions when the lesions are diffusely distributed and involving both lobes.

Based on this trial design, predict the completion outcome and termination type (if applicable).